Condition: Breast Cancer Female · Early-stage Breast Cancer · Lymph Node Metastases · Sponsor: Jewish General Hospital
RATIONALE: It is now standard for most breast cancer patients with 1-2 positive sentinel nodes to avoid completion node dissection when eligibility criteria from the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial are met. The National Comprehensive Cancer Network (NCCN) recently proposed to extend this indication to patients that present with biopsy proven node positive disease if only 1 or 2 suspicious nodes are found on imaging, these positive nodes are not palpable clinically, and the other eligibility criteria from the Z0011 study are otherwise met. However, this recommendation is based on an expert consensus and no study has yet confirmed the optimal method to stage the axilla in this patient population. PURPOSE: Evaluate the technical success rate and accuracy of sentinel node biopsy (SNB) and the potential benefits of clipping and removing the biopsy proven node using radioactive seed localisation (RSL) (SNB+RSL = Targeted Axillary Dissection (TAD)) in patients with biopsy proven positive nodes, limited nodal disease in imaging and clinically negative axillary examination.
This description comes directly from the study's public registry record.
Jean-François Boileau, MD,MSc,FRCSC · 514-340-8222 · jean-francois.boileau@mcgill.ca
Léamarie Meloche-Dumas, MD · 438-826-7489 · leamarie.meloche-dumas@umontreal.ca
Always discuss trial participation with your own doctor first.
| Hôpital Maisonneuve-Rosemont | Montreal, Quebec, Canada | Recruiting |
| Centre hospitalier de l'Université de Montréal | Montreal, Quebec, Canada | Recruiting |
| Jewish General Hospital | Montreal, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04671511